Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4785436
Max Phase: Preclinical
Molecular Formula: C25H34N4O6
Molecular Weight: 486.57
Molecule Type: Unknown
Associated Items:
ID: ALA4785436
Max Phase: Preclinical
Molecular Formula: C25H34N4O6
Molecular Weight: 486.57
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COCC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)c1cc2c(OC)cccc2[nH]1
Standard InChI: InChI=1S/C25H34N4O6/c1-14(2)10-19(29-25(33)20-12-16-17(27-20)6-5-7-22(16)35-4)24(32)28-18(21(30)13-34-3)11-15-8-9-26-23(15)31/h5-7,12,14-15,18-19,27H,8-11,13H2,1-4H3,(H,26,31)(H,28,32)(H,29,33)/t15-,18-,19-/m0/s1
Standard InChI Key: DDBOBUWAMRFUJW-SNRMKQJTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 486.57 | Molecular Weight (Monoisotopic): 486.2478 | AlogP: 1.55 | #Rotatable Bonds: 12 |
Polar Surface Area: 138.62 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.52 | CX Basic pKa: | CX LogP: 0.96 | CX LogD: 0.96 |
Aromatic Rings: 2 | Heavy Atoms: 35 | QED Weighted: 0.36 | Np Likeness Score: 0.02 |
1. Hoffman RL,Kania RS,Brothers MA,Davies JF,Ferre RA,Gajiwala KS,He M,Hogan RJ,Kozminski K,Li LY,Lockner JW,Lou J,Marra MT,Mitchell LJ,Murray BW,Nieman JA,Noell S,Planken SP,Rowe T,Ryan K,Smith GJ,Solowiej JE,Steppan CM,Taggart B. (2020) Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19., 63 (21): [PMID:33054210] [10.1021/acs.jmedchem.0c01063] |
Source(1):